Given the numerous p38MAPK inhibitors already in clinical development (Bachegowda et al., 2016; Patnaik et al., 2016), our findings provide strong pre-clinical data to extend these attempts to AML. focus on the importance of functional screening to identify common and actionable extrinsic pathways in genetically heterogeneous malignancies and provide impetus for medical development of IL-1/IL1R1/p38MAPK […]